Immunes
About
What is Immunes's revenue?
StartupHub estimates Immunes's annual revenue at $1.0M (range $553K to $1.6M, 27% confidence), based on comparable companies in the sector.
What is Immunes's valuation?
StartupHub estimates Immunes's effective valuation at $58.7M (range $40.0M to $96.0M, 10% confidence), based on comparable companies in the sector.
How much funding has Immunes raised?
Immunes has raised a total of $16M in funding. The most recent round on record is Seed.
What industry does Immunes operate in?
Immunes operates in AI-Driven Drug Discovery, Biotech, HealthTech, Drug Discovery, Clinical Trials, Foundation Model.
What is Immunes's current status?
Immunes's current operating status is: Inactive.
An AI-powered platform for cancer patients and survivors in Asia to navigate care and understand their diagnosis.
AI-powered platform for streamlining technical records, sample boundaries, and review processes.
AI-powered platform accelerating biological research and drug discovery.
AI-powered platform for personalized dental care and smile design.
A trusted, Apple-quality document assistant that transforms complex paperwork, medical reports, and legal notices into simple, actionable plain language for everyday life.
AI-driven platform for accelerating the discovery and design of novel toxins and therapeutic molecules.
Less keyboard, more patient. The clinical copilot that returns the joy of medicine to your practice.
Apimedtech is developing a novel platform for personalized medicine, leveraging AI and advanced analytics to improve patient outcomes.
An entrant is a company tagged AI-Driven Drug Discovery whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.